Treatment failure in intestinal strongyloidiasis: An indicator of HTLV-I infection
Treatment failure in intestinal strongyloidiasis: An indicator of HTLV-I infection
复制标题
DOI：
10.1016/s1201-9712(02)90132-3
复制
发表时间：
2002-03-01
影响因子：
8.4
通讯作者：
Gotuzzo, Eduardo
中科院分区：
文献类型：
--
作者：
Terashima, Angelica;Alvarez, Humberto;Gotuzzo, Eduardo
背景资料：严重类圆线虫病与HTLV-I的相关性是众所周知的，然而，在其他类圆线虫病人群中HTLV-I的血清阳性率仍然未知。我们在对伊维菌素或噻苯达唑标准治疗无效的肠类圆线虫病患者中进行了一项前瞻性研究（失败定义为治疗后随访时粪便检查阳性），这些患者没有已知的免疫抑制。所有患者均采用ELISA和Western Blot检测HTLV-Ⅰ。结果如下：对47例患者进行了评价：74.5%（35/47）为HTLV-I阳性，男性（76%）和女性（72.7%）之间无显著差异。结论：我们建议对所有标准治疗失败的无并发症的肠类圆线虫病患者进行HTLV-I感染的研究。
Background: The association of severe strongyloides with HTLV-I is well known; however, the seroprevalence of HTLV-I in other groups with strongyloidiasis is still unknown. We conducted a prospective study in patients with intestinal strongyloidiasis without known immunodepression who failed to respond to standard therapy with ivermectin or thiabendazole (failure was defined as one positive stool examination at the post-therapy follow up). All these patients were tested for HTLV-I by ELISA and Western Blot. Results: Forty seven patients were evaluated: 74.5% (35 out of 47) were HTLV-I positive, without significant difference between males (76%) and females (72.7%). Conclusions: We recommend that all patients with uncomplicated intestinal strongyloidiasis, who fail standard therapy, be studied for HTLV-I infection.